Source: International Congress 2018 – Orphan diseases in children
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
H. Marczak (Warszawa, Poland), J. Lange (Warszawa, Poland), K. Krenke (Warszawa, Poland), S. Boguslawski (Warszawa, Poland), K. Smalisz (Warszawa, Poland), I. Malinowska (Warszawa, Poland). Cladribine as a second line treatment in a child with isolated pulmonary Langerhans cell histiocytosis – case report. 623

Member's Comments

No comment yet.

Related content which might interest you: Chemotherapy in patients with pulmonary Langerhans cell histiocytosis Source: International Congress 2018 – Progress in rare interstitial lung diseases Year: 2018 How I manage pulmonary Langerhans cell histiocytosis Source: Eur Respir Rev, 26 (145) 170070; 10.1183/16000617.0070-2017 Year: 2017 Effect of cladribine therapy on lung cysts in pulmonary Langerhans cell histiocytosis Source: ERJ Open Res, 4 (1) 00089-2017; 10.1183/23120541.00089-2017 Year: 2018 Clinical features and outcome of adult patients with pulmonary Langerhans cell histiocytosis Source: International Congress 2019 – Innovative approaches for management and treatment of rare diffuse parenchymal lung diseases Year: 2019 Pneumothorax in patients with Langerhans cell histiocytosis Source: International Congress 2017 – The acute patient: the clinical point-of-view Year: 2017 Langerhans cell histiocytosis: is it an ILD? Source: Virtual Congress 2021 – Interstitial lung diseases Year: 2021 Psychological abnormalities are commonly present in adult patients with pulmonary Langerhans cell histiocytosis Source: International Congress 2019 – The changing face of rare diffuse parenchymal lung diseases: recent advances in pathogenesis, clinical manifestations and treatment Year: 2019 Lack of evidence for the involvement of Merkel cell polyomavirus in pulmonary Langerhans cell histiocytosis Source: ERJ Open Res, 6 (2) 00230-2019; 10.1183/23120541.00230-2019 Year: 2020 Effectiveness of chemotherapy treatment for patients with pulmonary Langerhans cell histiocytosis during long-term follow-up Source: Virtual Congress 2020 – Addressing unresolved questions in rare diffuse parenchymal lung diseases: interdisciplinary research is the key Year: 2020 Clinical impact of BRAFV600E mutation in adult pulmonary Langerhans cell histiocytosis Source: International Congress 2019 – Towards a better understanding of rare diffuse parenchymal lung diseases Year: 2019 Pneumothorax in pulmonary langerhans cell histiocytosis (PLCH) Source: International Congress 2018 – New insights in rare diffuse parenchymal lung diseases (DPLDs) in adults and children Year: 2018 Pulmonary Langerhans‘ cell histiocytosis (PLCH). Report of two cases diagnosed with pulmonary vascular involvement via exercise tests Source: Annual Congress 2008 - Miscellaneous aspects of interstitial lung disease Year: 2008 LAM, sarcoidosis, histiocytosis X – rare indications for lung transplantation – a single center experience Source: Eur Respir J 2007; 30: Suppl. 51, 175s Year: 2007 Pulmonary Langerhans' cell histiocytosis Source: Respipedia Article Year: 2016 Langerhans' cell histiocytosis: clinical and diagnostic features and response to therapy Source: Eur Respir J 2001; 18: Suppl. 33, 219s Year: 2001 Pulmonary Langerhans' cell histiocytosis Source: Eur Respir Mon; 2009: 46: 155–175 Year: 2009 Paediatric pulmonary Langerhans cell histiocytosis Source: Breathe, 16 (2) 200003; 10.1183/20734735.0003-2020 Year: 2020 Lung involvement in childhood Langerhans cell histiocytosis, A multi-institutional study from the french LCH study group Source: International Congress 2019 – Granulomatous disorders: from bench to bedside Year: 2019 Pulmonary Langerhans cell histiocytosis Source: Annual Congress 2008 - PG5 - Interstitial lung diseases: selected orphan diseases Year: 2008